Corient Private Wealth
JAZZ icon

Corient Private Wealth’s Jazz Pharmaceuticals JAZZ Stock Holding History

Corient Private Wealth’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.91M Sell
10,261
-16,652
-62% -$2.91M ﹤0.01% 1298
2025
Q4 		$3.37M Buy
26,913
+21,576
+404% +$3.31M ﹤0.01% 1246
2025
Q3 		$703K Sell
5,337
-1,100
-17% -$132K ﹤0.01% 1610
2025
Q2 		$669K Sell
6,437
-7,189
-53% -$781K ﹤0.01% 1550
2025
Q1 		$1.69M Buy
13,626
+2,769
+26% +$361K ﹤0.01% 1034
2024
Q4 		$1.34M Buy
10,857
+2,784
+34% +$328K ﹤0.01% 1181
2024
Q3 		$899K Buy
8,073
+307
+4% +$33.6K ﹤0.01% 1447
2024
Q2 		$829K Sell
7,766
-2,938
-27% -$323K ﹤0.01% 1401
2024
Q1 		$1.29M Sell
10,704
-508
-5% -$62.2K ﹤0.01% 1226
2023
Q4 		$1.38M Sell
11,212
-219
-2% -$27.3K ﹤0.01% 1163
2023
Q3 		$1.48M Buy
11,431
+145
+1% +$19.3K ﹤0.01% 1040
2023
Q2 		$1.4M Sell
11,286
-6,403
-36% -$861K ﹤0.01% 1034
2023
Q1 		$2.59M Sell
17,689
-770
-4% -$114K 0.01% 764
2022
Q4 		$2.94M Buy
+18,459
New +$2.71M 0.01% 611

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Corient Private Wealth's JAZZ Position: Q1 2026 in Review

Corient Private Wealth reduced its Jazz Pharmaceuticals (JAZZ) stake by 62% in Q1 2026, selling an estimated $2.91M and leaving 10,261 shares worth $1.91M. The position accounts for ﹤0.01% of the portfolio, ranked #1298.

Corient Private Wealth first reported a position in JAZZ in Q4 2022 and has held it in 14 quarters since. The position peaked at $3.37M in Q4 2025. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Corient Private Wealth held 10,261 shares of Jazz Pharmaceuticals worth $1.91M as of Q1 2026.
  • Corient Private Wealth sold 16,652 Jazz Pharmaceuticals shares in Q1 2026, an estimated $2.91M.
  • Jazz Pharmaceuticals made up ﹤0.01% of Corient Private Wealth's portfolio in Q1 2026, its #1298 holding.
  • Corient Private Wealth first reported a position in Jazz Pharmaceuticals in Q4 2022 and has held it in 14 quarters since.
  • Corient Private Wealth's Jazz Pharmaceuticals position peaked at $3.37M in Q4 2025.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Corient Private Wealth's 13F filing for Q1 2026, filed 15 May 2026.